and inhaled long-acting laninamivir octanoate hydrate (Inavir ® , laninamivir), have been mainly used for the treatment of influenza virus infections. These NAIs exert their antiviral function by binding to the enzymatic catalytic sites of influenza surface protein NA. 1 In the
2007-2008, oseltamivir-resistant seasonal A/H1N1 viruses carrying
NA amino acid (AA) mutation H275Y rapidly spread throughout the world. 2 We reported a prolonged duration of fever after administrating oseltamivir in patients infected with oseltamivir-resistant A/ H1N1 viruses during the 2008-2009 season in Japan, which demonstrated the association between clinical effectiveness and the acquisition of resistance to anti-influenza drugs. 3, 4 In the subsequent seasons, oseltamivir-resistant A/H1N1pdm09 viruses carrying H275Y were reported, 5 causing a concern for worldwide spread.
A global surveillance system has been developed to detect NAIresistant influenza isolates and their related NA AA mutations. 6 Currently, Japan is considered as the largest NAIs consuming country. 7 Thus, Japan is in an environment where the emergence and selection pressure of NAI-resistant influenza viruses are always strong compared with other countries and may become an epicenter of their global spread. Therefore, observing the transition of influenza NA AA mutations in Japan is considered important; however, comprehensive surveillance data, which include not only detecting NAI resistance and its related AA mutations but also determining NA AAs in epidemic viruses season by season, have not been fully reported in Japan. We have developed a network of physicians throughout Japan who routinely collect influenza virus samples, along with patient information. 3, 4 In this study, we sequenced the full length of NA genes of epidemic influenza viruses isolated in Japan during the seasons from 2011-2012 to 2016-2017 to detect their AA mutations and examine its relationship with NAI resistance. H1N1pdm09, 251 A/H3N2, and 80 B isolates, were analyzed to obtain NA sequencing data. Nasopharyngeal swabs for influenza virus isolation were collected, and the background history of patients who had a positive result on a rapid influenza antigen test, conducted in one of the member clinics of our nation-wide study network of general practitioners, was determined. Informed consent was obtained from all patients. All study participants were outpatients, and this study did not include any patients with severe chronic respiratory diseases, renal diseases, liver diseases, or heart failure. 
| MATERIAL S AND ME THODS

| Sample collection
| Influenza virus isolation and typing
| Sequencing
RT-PCR was performed using the A/H1N1pdm09, A/H3N2, and B RNA samples. 17, 18 After amplicon preparation, deep sequencing was conducted using the Illumina MiSeq sequencing system (Illumina, San Diego, CA, USA). Tables S1-S13.
| Nucleotide sequence accession number
The sequence data from this study were deposited into the DDBJ/ EMBL/GenBank nucleotide sequence databases under the following accession numbers: LC406948-LC407103, LC408965-LC409058, and LC409129-LC409257.
| Statistical analysis
Categorical variables were analyzed using the chi-square test. P value < 0.05 was considered to be statistically significant. All statistical analyses were performed using the jmp pro software, version 11
(SAS Institute, Inc., Cary, NC, USA).
| RE SULTS
The NA AA mutation rates were compared between catalytic and non-catalytic sites of each virus (Table 2) . Only five AA mutations were detected in the catalytic sites of A/H1N1pdm09 viruses, although their AA mutation rates at catalytic sites were not significantly different from those at non-catalytic sites (0.54% vs 0.45%).
For A/H3N2, only 13 AA mutations were detected in the catalytic sites. In the entire seasons examined, the AA mutation rates of A/ H3N2 viruses were significantly lower at catalytic sites than at noncatalytic sites (0.27% vs 0.65%, P = 0.001). No AA mutations were detected in the catalytic sites of B viruses, resulting in a significant lower frequency at the catalytic sites compared with those at the non-catalytic sites (0.0% vs 0.70%, P = 0.001). In the entire season examined, the AA mutations per sample at the catalytic sites of A/ H1N1pdm09, A/H3N2, and B were 0.10, 0.05, and 0.00 AAs, respectively, which confirmed the extremely low number in the AA mutations at the NA catalytic sites (Table S14) .
Based on the reports on NA AA mutations associated with reduced inhibition by NAIs, 2,6,20 RI/HRI-related AA mutations were extracted from NA sequencing data examined in this study (Table 3) .
Most (10/13 mutations) of the AA mutations detected in the catalytic sites of A/H3N2 viruses were D151G/N mutations, which were found to be induced by an MDCK cultivation. the non-catalytic sites was also reported to be associated with an MDCK passage. 23 These AA mutations were not detected in any of unpassaged clinical samples. 22 Finally, few AA mutations (3/4769, 0.06%, referred to Table 2 Table S8 ). D199N in A/H1N1pdm09, D151E, K249E, G320E, and S331R in A/H3N2, and I262T in B were extracted as RI/HRI-related AA mutations, based on their related references 6,24-26 ; however, no virus harboring these AA mutations showed substantial RI/HRI based on their IC 50 values.
| D ISCUSS I ON
In this study, the detection rates of NAI-resistant influenza viruses and their related NA AA mutations were analyzed from comprehensive NA sequencing data of epidemic isolates in Japan, where NAIs are massively used. Consequently, NA AA mutations associated with NAI resistance were only H275Y of H1N1pdm09. The frequency of H275Y detected in Japan was approximately 1%, which was similar to that reported by a global surveillance. 6 For A/H3N2 and B, no virus exhibiting reduced inhibition by NAIs was detected in Japan. These results were also similar to those reported by a global surveillance, which indicated that NAI-resistant A/H3N2 and B viruses were detected at a lower frequency (<1.0%) compared with NAI-resistant A/H1N1pdm09 viruses. 6 This study showed that few AA mutations in the catalytic sites of A/H3N2 viruses were found without their D151G/N mutations. Our findings suggested that the AA mutations in the NA catalytic sites were far more difficult to occur than those in the non-catalytic sites, at least for A/H3N2 and B viruses. The acquisition of NAI resistance-related mutations in epidemic influenza viruses does not seem to occur easily, even in Japan.
In this study, the detection rates of AA mutations in the noncatalytic sites of NA genes were also examined, and relatively many mutations to the catalytic sites were detected. In addition, the AA mutations associated with reduced inhibition by NAIs, which were indicated by the previous reports, were also included in their mutations.
However, these presumed NAI resistance-related mutations did not show any substantial reduced inhibition in this study (Table 3 ). These findings suggested that the direct contribution of mutations in the NA non-catalytic sites to NAI resistance was extremely rare.
This study showed that oseltamivir-resistant A/H1N1pdm09 viruses carrying H275Y did not spread throughout Japan. The sporadic community spread of the H275Y-resistant viruses was reported in Newcastle, Australia, in 2011 and in Sapporo, Japan, in 2013. 27, 28 These viruses discovered in the two cities carried additional AA mutations, V241I and N369K, which were presumed to confer a positive effect on viral fitness. 29 These viruses were also shown to have carried the third additional AA mutation, AA, amino acid; HRI, highly reduced inhibition; IC 50 , 50% inhibitory concentration; NA, neuraminidase; NAIs, neuraminidase inhibitors; RI, reduced inhibition.
RI/HRI-related AA mutations were extracted from NA sequencing data examined in this study, based on the previous reports.
The AA position numberings of A/H1N1pdm09, A/H3N2, and B viruses are based on N1, N2, and B type-specific numbering, respectively. Median IC 50 values and fold changes are shown in Tables S1-S13.
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N386S/K, which was in contrast suggested to cause a negative effect on viral fitness in the presence of the V241I and N369K mutations. 29, 30 In our data (Table S15) (Table 3 ).
The mechanism of acquiring drug resistance in NA catalytic sites for zanamivir and laninamivir is different from that for oseltamivir and peramivir, due to a difference in their side chain structures. 31 Laninamivir is licensed only in Japan and has been used increasingly in the last few years, being the main NAI used. No mutations associated with laninamivir resistance were detected in our study. This finding also suggests that the NA catalytic sites of influenza viruses are well preserved. Even in Japan, the largest consumer of NAIs, no spread of NAI-resistant viruses with mutations related to clinical ineffectiveness, such as a prolonged duration of fever, has been observed, and the emergence of A/H1N1pdm09 viruses carrying H275Y remains limited.
NAIs are currently effective for the treatment of influenza virus infections, although a continued surveillance is warranted in the future.
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